News

Even patients who were never hospitalized for COVID-19 face a heightened risk of cardiovascular issues. #longcovid

Stroke is typically seen as the biggest danger for patients after they receive an AFib diagnosis. This study, however, suggests heart failure could be an even bigger threat.

TAVR JenaValve Trilogy Heart Valve System pure AR

The 65-year-old male patient presented with a long medical history and many comorbidities, making surgery too risky.

2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.

How have recent FDA approvals for Edwards Lifesciences and Abbott changed patient care? Andrew Rassi, MD, answered that question—and many more—in a new interview. 

the words "FDA recall" on a board

There have been a total of 11 incidents so far, including seven injuries and two deaths. Boston Scientific said the agent can still be used if operators follow specific instructions during lower GI bleed embolization procedures.  

Video interview with ACC President Cathie Biga on goals for college over the next year and trends she saw at ACC 2024.

Biga, who originally trained as a nurse, specializes in the business side of cardiology. She also emphasized the increasing importance of AI and other new technologies. 

pharmaceutical drug approval process

The new gene therapy candidate is now one step closer to being approved by the FDA. 

A study that analyzed patient outcomes in coronary artery bypass grafting (CABG) in veterans showed outcomes for on-pump and off-pump procedures over 10 years to be similar. Photo by Jim Lennon

Finding new ways to avoid intraoperative anemia could go a long way toward improving outcomes for female CABG patients. The full analysis, based on more than 1.4 million patients, was published in the Journal of the American College of Cardiology.

Performing CT-derived fractional flow reserve (CT-FFR) before transcatheter aortic valve replacement (TAVR) improves the accuracy of coronary CT angiography (CCTA) and helps limit unneeded invasive coronary angiography (ICA), according to a new study published in JACC: Cardiovascular Interventions. Heartflow

Radiologists with Massachusetts General Hospital found that the selective use of cardiac CT and AI-based CAD evaluations could make a significant impact on patient care. 

Three transcatheter tricuspid valve repair and replacement (TTVR) technologies that will likely see FDA clearance in. the next couple years include the Edwards Evoque transcatheter tricuspid valve (top left), Abbott TriClip (below) and the Edwards Lifesciences Pascal clip device (right).

The complexity of the mitral valve has slowed development of new transcatheter technologies, and it now seems much more likely that transcatheter devices for tricuspid valve will push ahead to gain FDA clearances.

Thermedical SERF thermal ablation system for VT.

The FDA has approved a clinical trial to evaluate the safety and efficacy of a new type of ablation catheter for patients with ventricular tachycardia (VT) resistant to conventional anti-arrhythmic drugs or standard ablation procedures.

Interview with Rebecca T. Hahn, MD, Professor of Medicine at Columbia University Irving Medical Center, Chief Scientific Officer of the Echo Core Lab at the Cardiovascular Research Foundation and Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center. She discusses some of the trends of growing use of interventional echocardiographic guidance in transcatheter structural heart procedures, the growing number of tricuspid valve procedures, and use of 3D ICE.

Rebecca T. Hahn, MD, Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center, discusses some of the trends in the growing use of interventional echocardiographic guidance in transcatheter structural heart procedures.

The Abbott MitraClip is the primary structural heart device used in transcatheter edge-to-edge repairs (TEER) of the mitral valve leaflets. The results of the COAPT trial dropped like a thunderclap Sunday at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, with several cardiologists predicting the MitraClip device will have a swift and lasting impact on the treatment of heart failure patients.

When these malfunctions occur, the FDA explained, it leads to an increased risk of additional interventions.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.